A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Inclusion Criteria:

1. Participants with Progressive forms of Multiple Sclerosis including PrimaryProgressive and Secondary Progressive MS.

2. Participants must have discontinued disease modifying therapy (DMT) prior to signingthe ICF and meet the following washout criteria prior to receiving lymphodepletion.

Exclusion Criteria:

1. History of malignancy that has not been in remission for at least 2 years.

2. Viral Screening

3. Evidence of chronic active or history of hepatitis B virus (HBV).

4. Seropositive for human immunodeficiency virus (HIV) antibody.

5. History of bone marrow/hematopoietic stem cell or solid organ transplantation.

6. Prior treatment with adoptive T-cell therapy or any gene therapy product directed atany target (e.g. CAR T-cell therapy).

Note: Please note, other protocol specified Inclusion/Exclusion criteria may apply.